Search results for "PEPTIDE"

showing 10 items of 4589 documents

Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease.

2012

Abstract Aims and background Midregional proadrenomedullin (MR-proADM) is a protein, which exerts various effects on the cardiovascular system. Recent studies underscored its prognostic implications in patients with acute dyspnea and cardiovascular diseases. Therefore, we aimed to determine the distribution of MR-proADM in the general population and to reveal potential associations of MR-proADM with cardiovascular risk factors and measures of subclinical cardiovascular disease. Methods and results MR-proADM plasma concentrations were determined in individuals of the population-based cohort of the Gutenberg Health Study ( N  = 5000) using a commercially available fluoroimmunoassay. Individua…

AdultMalemedicine.medical_specialtyPopulationFluoroimmunoassayRisk AssessmentCoronary artery diseaseAdrenomedullinSex FactorsPredictive Value of TestsRisk FactorsInternal medicineGermanymedicinePrevalenceHumansMyocardial infarctionProspective StudiesProtein PrecursorseducationSubclinical infectionAgededucation.field_of_studybusiness.industryAge FactorsMiddle Agedmedicine.diseasePrognosisPeptide FragmentsUp-RegulationCross-Sectional StudiesPhenotypeIntima-media thicknessCardiovascular DiseasesEchocardiographyHeart failureAsymptomatic DiseasesCardiologyLinear ModelsPopulation studyFemaleCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkersAtherosclerosis
researchProduct

Polymorphisms in the SCD1 gene are associated with indices of stearoyl CoA desaturase activity and obesity: a prospective study.

2013

Scope The serum fatty acid (FA) composition is influenced by dietary fat and the endogenous production of FAs. Stearoyl CoA desaturase 1 (SCD1) is the rate-limiting enzyme catalyzing the synthesis of MUFAs from saturated FAs. Variations in SCD1 activity have been associated with obesity, diabetes, or inflammation. We evaluated the associations between genetic variation of the SCD1 gene, SCD1 activity, intake of oil, and obesity in a population-based prospective study in southern Spain. Methods and results We collected phenotypic, metabolic, nutritional, and genetic information. The type of dietary fat was assessed from samples of cooking oil taken from the participants’ kitchens and analyze…

AdultMalemedicine.medical_specialtyPopulationSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideInternal medicineGenetic variationmedicineHumansPlant OilsGenetic Predisposition to DiseaseCookingObesityProspective StudieseducationOlive OilPhospholipidschemistry.chemical_classificationeducation.field_of_studyFatty acidMiddle Agedmedicine.diseaseObesityDietary FatsEnzyme assayStearoyl-CoA DesaturaseEndocrinologyBiochemistrychemistryHaplotypesSpainbiology.proteinlipids (amino acids peptides and proteins)Stearoyl-CoA desaturase-1Stearoyl-CoA DesaturaseFood ScienceBiotechnologyMolecular nutritionfood research
researchProduct

Modulation of adrenergic responses of human vas deferens by K+ channel inhibitors.

2010

Objectives The present study was designed to evaluate the role of K + channels in the adrenergic responses of human vas deferens as well as the intervention of dihydropyridine-sensitive Ca 2+ channels on modulation of adrenergic responses by K + channel inhibitors. Methods Ring segments of the epididymal part of the vas deferens were taken from 32 elective vasectomies and mounted in organ baths for isometric recording of tension. We then studied the effects of K + channel blockers on neurogenic and norepinephrine-induced contractile responses. Results Addition of tetraethylammonium (TEA, 10 −3 M), a nonspecific K + channel blocker, or charybdotoxin (10 −7 M), a nonselective inhibitor of lar…

AdultMalemedicine.medical_specialtyPotassium ChannelsCharybdotoxinCalcium Channels L-TypeCharybdotoxinNifedipineUrologyAdrenergicApaminGlibenclamidechemistry.chemical_compoundNorepinephrineVas DeferensNifedipineInternal medicineReceptors Adrenergic alpha-1GlyburidePotassium Channel BlockersMedicineHumansChannel blockerTetraethylammoniumIon Transportbusiness.industryVas deferensTetraethylammoniumMuscle SmoothElectric StimulationEndocrinologymedicine.anatomical_structurechemistryApaminPotassiumCalciumbusinessPeptidesmedicine.drugMuscle ContractionUrology
researchProduct

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

2020

Digital

AdultMalemedicine.medical_specialtyRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansHypoglycemic AgentsCognitive DysfunctionRisk factorAgedbusiness.industryHazard ratioMontreal Cognitive AssessmentMiddle Agedmedicine.diseaseImmunoglobulin Fc FragmentsTreatment OutcomeDiabetes Mellitus Type 2Digit symbol substitution testFemaleDulaglutideNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Human Corticotropin-Releasing Hormone in Man: Dose-Response of Minute Ventilation and End-Tidal Partial Pressures of Carbon Dioxide and Oxygen*

1987

The respiratory stimulant properties of iv injections of 33, 67, and 100 micrograms synthetic human corticotropin-releasing hormone (hCRH) were studied in 12 normal men in a single blind, placebo-controlled trial. All doses of hCRH induced a respiratory stimulation in every subject, and the stimulation was dose dependent. The onset of respiratory stimulation occurred within 15-30 sec after hCRH infusion was started. Initially, there was an increase in tidal volume (VT), followed by an increase in respiratory rate. The maximum minute ventilation (VE) occurred 60-120 sec after starting the injection. The 33-micrograms hCRH dose induced a 35% increase in VE from 6.3 +/- 0.6 (+/- SD) to 9.7 +/-…

AdultMalemedicine.medical_specialtyRespiratory rateCorticotropin-Releasing HormonePartial PressureEndocrinology Diabetes and MetabolismClinical BiochemistryBlood PressureStimulationPeptide hormoneBiochemistryEndocrinologyDouble-Blind MethodHeart RateInternal medicineHeart rateFlushingmedicineHumansRespiratory systemTidal volumeDose-Response Relationship DrugChemistryRespirationBiochemistry (medical)Carbon DioxideOxygenEndocrinologyAnesthesiaBreathingRespiratory minute volumeThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increas…

2005

Triglyceride-rich lipoproteins generated during the postprandial phase are atherogenic. Large very low-density lipoproteins (LDLs) or chylomicrons (CMs) are not as atherogenic as their remnants (Rem). Small and dense LDLs are associated with cardiovascular disease. Low-density lipoprotein size is partly under genetic control and is considered as a relatively stable LDL feature. In this article, we present data on retinyl palmitate kinetics correlated with the modification of LDL features in terms of size, density, and in vitro receptor binding affinity after an oral fat load. Six nondiabetic, hypertriglyceridemic (HTG) patients and 6 healthy controls were examined. Low-density lipoprotein s…

AdultMalemedicine.medical_specialtyRetinyl EstersSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismBinding CompetitiveModels Biologicalchemistry.chemical_compoundEndocrinologyInternal medicineRetinyl palmitateCell Line TumorChylomicronsmedicineHumansReceptorVitamin AHypertriglyceridemiaLow-density lipoproteins hypertriglyceridemia Fasting and postprandial LDLsTriglycerideCatabolismChemistryFastingFibroblastsPostprandial PeriodDietary FatsLipidsLipoproteins LDLKineticsEndocrinologyPostprandialReceptors LDLlipids (amino acids peptides and proteins)Density gradient ultracentrifugationElectrophoresis Polyacrylamide GelFemaleDiterpenesUltracentrifugationLipoproteinChylomicronMetabolism: clinical and experimental
researchProduct

Human infant saliva peptidome is modified with age and diet transition.

2012

Abstract In order to describe developmental changes in human salivary peptidome, whole saliva was obtained from 98 infants followed longitudinally at 3 and 6 months of age. Data on teeth eruption and diet at the age of 6 months were also recorded. Salivary peptide extracts were characterised by label-free MALDI-MS. Peptides differentially expressed between the two ages, and those significantly affected by teeth eruption or introduction of solid foods were identified by MALDI TOF–TOF and LC ESI MS–MS. Out of 81 peaks retained for statistical analysis, 26 were overexpressed at the age of 6 months. Exposure to solid foods had a more pronounced effect on profiles (overexpression of nine peaks) …

AdultMalemedicine.medical_specialtySalivaAgingProteomeBiophysicsBiology01 natural sciencesBiochemistryTooth Eruption03 medical and health sciencesstomatognathic systemInternal medicinemedicineHumansStatistical analysisWhole salivaSalivary Proteins and PeptidesSalivaComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesChromatographyTransition (genetics)010401 analytical chemistryInfantFeeding Behavior0104 chemical sciencesEndocrinologySolid foodHistatinSalivary ProteinsFemalePeptides[SDV.AEN]Life Sciences [q-bio]/Food and NutritionJournal of proteomics
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.

2014

Background: The objective of this study is to determine whether simvastatin consumption and hyperlipidemia are associated with a worse periodontal condition and specific bone activity biomarkers. Methods: This cross-sectional and analytic study includes 73 patients divided into three groups: 1) simvastatin-treated patients with hyperlipidemia (n = 29); 2) patients with hyperlipidemia treated by diet alone (n = 28); and 3) normolipidemic patients (controls, n = 16). The periodontal clinical variables of all participants were gathered, a blood sample was drawn from each to determine the lipid profile (total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein), se…

AdultMalemedicine.medical_specialtySimvastatinAlcohol DrinkingOsteocalcinHyperlipidemiasBlood SedimentationCollagen Type IBone remodelingN-terminal telopeptideInternal medicineHyperlipidemiaPeriodontal Attachment LossmedicineHumansTriglyceridesAgedHypolipidemic AgentsPeriodontitismedicine.diagnostic_testbusiness.industryCholesterol HDLSmokingOsteoprotegerinnutritional and metabolic diseasesCholesterol LDLMiddle Agedmedicine.diseasePeptide FragmentsEndocrinologyC-Reactive ProteinCholesterolCross-Sectional StudiesClinical attachment lossSimvastatinErythrocyte sedimentation ratePeriodonticsFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsPeriodontal IndexbusinessLipid profilePeptidesBiomarkersProcollagenmedicine.drugJournal of periodontology
researchProduct

Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial

2010

Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL subfraction distribution. Methods and results A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 ± 30 mg/dL (2.9 ± 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24), or their combination ( n = …

AdultMalemedicine.medical_specialtySimvastatinRandomizationCombination therapyAdolescent10265 Clinic for Endocrinology and Diabetology610 Medicine & health2705 Cardiology and Cardiovascular Medicinelaw.inventionYoung AdultRandomized controlled trialEzetimibelawInternal medicinemedicineDistribution (pharmacology)HumansDrug Interactionsbiologybusiness.industryAnticholesteremic AgentsLipoprotein(a)Middle AgedEzetimibeLipoproteins LDLEndocrinologySimvastatinMultivariate Analysisbiology.proteinAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationElectrophoresis Polyacrylamide GelatherosclerosisCardiology and Cardiovascular MedicinebusinessBody mass indexmedicine.drug
researchProduct